Purpose: Building on previous research, we examined whether delayed study start and low patient accrual rates found in 31 postauthorization registry-based studies requested by European Medicines Agency (EMA) are maintained after 2 additional years of follow-up.
| BACKGROUND AND PREVIOUS FINDINGS
Postauthorization studies based on patient registries are frequently requested to marketing authorization holders by regulatory authorities to support the benefit-risk monitoring of their licensed drugs. of these imposed studies had not started, 50% were ongoing, and less than 10% had been completed. The issues most commonly identified by the EMA in this review were delayed time to start and low patient accrual rates. Based on these results, the EMA recommended the use of existing patient registries to improve the timeliness of data collection in the postmarketing setting.
The current study examines whether these critical issues still apply to the 31 registry-based studies after a longer observation period (follow-up extended by 2 years until November 30, 2017).
The new findings will be further considered in the EMA initiative for patient registries that aim to make better use of existing registries for regulatory purposes. 4 
| METHODS
The list of registries identified in the previous EMA study and the same methodology were used in this study. The information available for the following variables was updated: marketing authorization status, study and registry status, study end date, planned duration and number of patients planned to be enrolled, and actual patients enrolled. These data were collected from several combined nonpublic in-house sources such as study protocols, interim and final study reports, risk management plans, and periodic safety update reports.
As discussed, in the initial study, the terms "registry" and "study"
are sometimes used interchangeably. In this follow-up study, we distinguished between the situation in which regulators specifically imposed a requirement to establish a registry as a systematic data collection tool and the situation in which a specific postauthorization study was imposed with specific objectives and a study design involving the use of a registry as the data collection tool. 4 To illustrate the progress of the studies, we defined the "patient accrual percentage" as the number of patients currently enrolled in the study divided by the number of planned patients, and the "study progression status" as actual study duration (from first patient enrolled until last date of data collection) divided by the planned study duration.
3 | RESULTS
| Study status
As b All the studies/registries in the "not started" category are related to products for which the marketing authorizations have been withdrawn. Table 1 ).
For 11 of the 14 ongoing studies and for 8 of the 10 finalized studies, available information allowed to calculate either study progression status or accrual percentage (Figure 1) . Among the ongoing studies, 4 were still within the original agreed timeframe (progression status <100%) with 1 study already surpassing the targeted number of patients, and 5 were delayed by a median of 5 years (range: 1-7 years) with patients' accrual lower than 50% for 4 of them (1 had missing data). Among the finalized studies, 6 had a delayed completion with a median delay of 3 years (range: 2-6 years). Three finalized studies managed to reach or surpass 100% of patients' accrual.
Fifty percent of studies conducted within disease registries and 33% of studies conducted within product registries were delayed compared with the planned finalization date.
As of November 2017, the median patients' accrual percentages were 24% for ongoing studies and 101% for finalized studies, as compared with 8.5% and 24% in June 2015.
| Registry status
Compared with the previous period, 2 (6.4%) more registries started data collection and 7 (22.6%) more were finalized. Five registries (16%) are open-ended (Table 1) .
Both for studies and registries, missing data were common, highlighting an omission to report essential information to regulators.
The following variables were most affected: planned duration (26% missing data), planned patients (9.7% missing data), number of actual patients, and study end date (6.5% missing data).
| DISCUSSION AND CONCLUSION
This update shows that 32.2% of registry-based studies were finalized as of November 2017 as compared with 9.7% as of June 2015. The overall patient accrual was higher than in the first period, both for ongoing and finalized studies.
Overall, the conclusions reached in the initial EMA study remain valid after a longer follow-up period: Both the rate of recruitment and timely finalization are challenging for registry-based studies. A reason may be that most of the investigated products are orphan or specialized products with a very small target population. This should be taken into consideration during the study design stage when realistic study timeframes and planned patient numbers should be proposed.
Although several nonpublic data sources were consulted, consistent information on planned duration, planned/actual patients, and study end date was still difficult to identify. The current results therefore support the need for more systematic, transparent, and standardized approach for the conduct and reporting of registry-based studies. It should be highlighted that most of the studies identified in the initial study were imposed before the new EU pharmacovigilance legislation took effect in July 2012. 5 The new legislation requires the review of the study protocols and results by the Pharmacovigilance and Risk Assessment Committee and the registration of imposed postauthorization safety studies in the EU PAS Register. 6 These measures should, at least in theory, lead to an improvement in reporting. An evaluation of registry-based studies imposed after July 2012 should identify whether improvements have been made following the new EU pharmacovigilance legislation, and this may be an area of future research for EMA.
Most registries used for imposed studies in this review are product registries, with patient entry based on exposure to a specific drug.
The EMA's Patient Registries Initiative initiated in 2015 4 strongly recommends use of "disease registries," covering a wider population defined by a particular condition that is followed over time regardless of the products administered. As disease registries are generally integrated in health systems and clinical practice, they may be associated with better accesibility to data.
European Medicines Agency is already aware of the challenges in using registries to monitor the safety of marketed medicines. To this end, EMA has held 2 specific registry workshops on cystic fibrosis and multiple sclerosis diseases. 7, 8 The analysis performed at these workshops highlighted that registries do not often collect routinely all the data needed for a postauthorization study. This may be due to the limited standardization of data elements captured by national and international registries, the inadequate data quality control, the time lag between the data collection and data availability, as well as a possible misunderstanding by regulators of the ability of a given registry to collect data on specific regulatory concerns. These aspects are currently being addressed through the EMA initiative for patient registries focusing on efficient collaboration among medicine regulators, pharmaceutical companies, and various registry coordinators. A certification process could ensure users that the data are of acceptable quality for regulatory purposes. As a first example in this direction, the European Cystic Fibrosis Society Patient Registry 9 undertook an EMA qualification procedure to assess whether its' data collection system is adequate to support regulatory decision making. 10 Overall, the data from this report are encouraging but show that further work are needed to facilitate use of registry data for regulatory purposes, a work that has already been started via the EMA registry initiative.
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